文献速递湿疹皮炎与荨麻疹

德国慢性荨麻疹患者的流行病学、合并症与医疗资源利用

Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-11-12

BACKGROUND: Comprehensive data on the epidemiology and comorbidities of chronic urticaria (CU) in Germany are either limited, or not contemporary.…

要点

  • 德国CU患病率约0.5%,女性高于男性。
  • 常见合并症包括高血压、脂蛋白代谢紊乱和情感障碍。
  • 54.1%的CU患者未接受任何处方治疗。

核心结论

  • 德国CU患病率约0.5%,合并多种疾病可能增加医疗系统负担。
  • 需提高对治疗指南的遵循意识,以实现荨麻疹的完全控制。

研究设计与样本

  • 基于德国柏林应用健康研究所匿名法定健康保险理赔研究数据库(2015年1月1日至2018年9月30日)的回顾性分析。

主要发现

  • CU亚型分布:慢性自发性荨麻疹(CSU)71.2%,慢性诱导性荨麻疹(CIndU)19.7%,CSU+CIndU 9.1%。
  • 女性CU诊断患病率0.62%、发病率0.18%,男性分别为0.37%和0.11%。
  • 患者最常就诊于全科医生,占总就诊次数的41.3%。
  • 常见合并症:高血压病43.5%、脂蛋白代谢紊乱32.1%、情感障碍26.0%。

关键数值与推荐

  • 大多数关注的合并症发生率与特应性皮炎和银屑病患者相似,且均高于总体人群。
  • 54.1%的CU患者未接受任何处方治疗。
  • 第二代H1抗组胺药是最常用处方药物,成人17.9%、儿童27.9%。
  • CIndU患者住院比例(儿童15.5%、成人7.8%)高于CSU患者(儿童9.9%、成人4.6%)。

临床怎么用

  • 临床应关注CU患者的高血压、脂蛋白代谢紊乱和情感障碍等合并症筛查与管理。
  • 超过半数CU患者未获处方治疗,提示需提高指南遵循率和治疗可及性。
  • 第二代H1抗组胺药是常用治疗,但需追求荨麻疹完全控制以改善结局。
  • CIndU患者住院风险较高,应加强识别与管理。

局限性

  • 基于保险理赔数据库,诊断依赖ICD编码,可能存在误分类。
  • 仅纳入德国法定健康保险人群,结果外推需谨慎。
  • 未报告治疗依从性、疾病严重度及患者报告结局等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comprehensive data on the epidemiology and comorbidities of chronic urticaria (CU) in Germany are either limited, or not contemporary. OBJECTIVES: To investigate the epidemiology of CU, overall comorbidities and healthcare resource utilized by patients with CU in Germany, using an anonymized statutory health insurance (SHI) database. METHODS: Anonymized SHI claims research database of the Institute for Applied Health Research, Berlin [InGef] (01 January 2015-30 September 2018) was used to analyse insured individuals with a confirmed diagnosis of CU (ICD-10-GM codes). Twelve-month diagnosed prevalence and incidence, comorbidities (vs. atopic dermatitis and psoriasis), and healthcare utilization by patients with CU were investigated. RESULTS: Of 4 693 772 individuals of all ages listed in the database, 3 538 540 were observable during 2017. Overall, 17 524 patients (˜0.5%) were diagnosed with CU; chronic spontaneous urticaria (CSU: 71.2%), chronic inducible urticaria (CIndU: 19.7%), CSU+CIndU (9.1%). Females, vs. males, had higher diagnosed prevalence (0.62% vs. 0.37%) and diagnosed incidence (0.18% vs. 0.11%) of CU among all patients. Patients most frequently visited general practitioners (41.3% of total visits). Hypertensive diseases (43.5%), lipoprotein metabolism disorders (32.1%) and affective disorders (26.0%) were the most frequently reported comorbidities of special interest. Rates of most comorbidities of special interests were similar to atopic dermatitis and psoriasis patients, and all higher vs. overall population. More than half (54.1%) of all CU patients were not prescribed any treatment. Second-generation H1 -antihistamines were the most commonly prescribed medication for adult (17.9%) and paediatric (27.9%) patients. Patients with CIndU (paediatric, 15.5%; adult, 7.8%) were more often hospitalized versus patients with CSU (paediatric, 9.9%; adult, 4.6%). CONCLUSIONS: In Germany, prevalence of CU along with multiple comorbidities may pose increased burden on the healthcare system. Awareness of adhering to treatment guidelines, and aiming for complete control of urticaria, needs to be driven and may improve outcomes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Weller K, Maurer M, Bauer A, et al. Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. J Eur Acad Dermatol Venereol. 2021. PMID: 34622498. doi:10.1111/jdv.17724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。